Zacks Investment Research Downgrades Vicarious Surgical (NYSE:RBOT) to Sell

Vicarious Surgical (NYSE:RBOTGet Rating) was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a research note issued on Thursday, Zacks.com reports.

According to Zacks, “Vicarious Surgical Inc. is a robotics company developing a disruptive technology. The Company’s novel surgical approach uses a combination of proprietary human-like surgical robots and virtual reality to transport surgeons inside the patient to perform minimally invasive surgery. Vicarious Surgical Inc., formerly known as D8 Holdings Corp., is headquartered in Waltham, Mass. “

Several other analysts also recently commented on the stock. Piper Sandler downgraded shares of Vicarious Surgical from an “overweight” rating to a “neutral” rating and cut their price objective for the company from $16.00 to $7.00 in a research report on Friday, March 4th. Credit Suisse Group started coverage on shares of Vicarious Surgical in a report on Friday, January 7th. They set an “outperform” rating and a $16.00 price target on the stock. One analyst has rated the stock with a sell rating, one has issued a hold rating and four have given a buy rating to the company’s stock. According to data from MarketBeat.com, Vicarious Surgical has a consensus rating of “Buy” and a consensus target price of $12.33.

Shares of RBOT stock opened at $4.80 on Thursday. Vicarious Surgical has a one year low of $3.98 and a one year high of $15.79. The company’s 50-day moving average is $4.99 and its 200 day moving average is $7.98. The company has a debt-to-equity ratio of 0.01, a current ratio of 28.56 and a quick ratio of 28.56.

Vicarious Surgical (NYSE:RBOTGet Rating) last announced its quarterly earnings data on Thursday, March 3rd. The company reported ($0.15) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.11) by ($0.04). Analysts predict that Vicarious Surgical will post -0.58 earnings per share for the current year.

In related news, CEO Adam David Sachs sold 8,537 shares of the firm’s stock in a transaction that occurred on Monday, March 28th. The shares were sold at an average price of $4.23, for a total value of $36,111.51. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Also, CTO Sammy Khalifa sold 6,830 shares of the firm’s stock in a transaction that occurred on Thursday, April 14th. The stock was sold at an average price of $4.08, for a total transaction of $27,866.40. Following the completion of the transaction, the chief technology officer now directly owns 136,413 shares in the company, valued at approximately $556,565.04. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 35,842 shares of company stock worth $152,359.

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Advisor Group Holdings Inc. bought a new stake in Vicarious Surgical during the 3rd quarter worth approximately $27,000. BlackRock Inc. bought a new stake in Vicarious Surgical during the 3rd quarter worth approximately $32,000. Rockefeller Capital Management L.P. bought a new stake in Vicarious Surgical during the 3rd quarter worth approximately $59,000. Citigroup Inc. bought a new stake in Vicarious Surgical during the 4th quarter worth approximately $47,000. Finally, Nauset Wealth Management. LLC bought a new stake in shares of Vicarious Surgical during the first quarter valued at approximately $26,000. Institutional investors own 35.25% of the company’s stock.

About Vicarious Surgical (Get Rating)

Vicarious Surgical Inc operates as a robotics technology company in the United States. The company focuses on developing and commercializing Vicarious System, a single-incision surgical robot that virtually transports surgeons inside the patient to perform minimally invasive surgery. Vicarious Surgical Inc was incorporated in 2014 and is headquartered in Waltham, Massachusetts.

Featured Stories

Get a free copy of the Zacks research report on Vicarious Surgical (RBOT)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Vicarious Surgical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vicarious Surgical and related companies with MarketBeat.com's FREE daily email newsletter.